CC BY-NC-ND 4.0 · Avicenna J Med 2016; 06(03): 69-74
DOI: 10.4103/2231-0770.184063

CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study

Mousa A Al-Abbadi
Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia
Mohammed J Al-Yousef
Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia
Mohammad M Yousef
Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia
Salwa S Sheikh
Department of Pathology and Laboratory Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia
Nidal M Almasri
Department of Pathology and Laboratory Medicine, Saad Specialist Hospital, Al Khobar, Kingdom of Saudi Arabia
Samir S Amr
Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia
› Author Affiliations
Financial support and sponsorship Department of Pathology and Laboratory Medicine at King Fahad Specialist Hospital, Dammam, Saudi Arabia.


Giant cell tumor of bone (GCTB) is a primary bone neoplasm which is characterized by the presence of mononuclear cells (MCs) and osteoclast-like multinucleated giant cells (MNGCs). Up to our knowledge, CD10 immunoreactivity in GCTB has not yet been studied, and only one study touched on CD138 immunoreactivity in GCTB. The objective of this study is to investigate the immunoreactivity of CD10 and CD138 in GCTB. We offer a discussion of our findings in the context of the differential diagnosis, particularly in small biopsy material. We retrieved and reviewed 15 well-documented cases of GCTB from January 2008 to December 2014. Well-controlled standard immunohistochemical satins were performed on these cases for CD10 and CD138 and few other selected antibodies. Immunoreactivity for CD10 was membranous and was found in 14 (93%) cases. This immunoreactivity was found only in the MCs, whereas the MNGC were all negative. CD138 showed variable positivity in 11 (73%) while 4 (37%) were completely negative. Similar to CD10, staining for CD138 was only seen in the MC; however, the immunoreactivity was predominantly concentrated in the peri-vascular areas. Most of GCTB cases can show variable immunoreactivity for CD10 and CD138. The aforementioned immune-expression raise the possibility of a role in the pathogenesis of GCTB. Paying attention to this immunoreactivity is recommended when considering the clinical and radiological differential diagnosis, especially in small biopsy specimens.

Publication History

Article published online:
09 August 2021

© 2016. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

  • References

  • 1 Lucas DR. Giant cell tumor of bone. Surg Pathol Clin 2012;5:183-200.
  • 2 Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol 2009;21:338-44.
  • 3 Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7.
  • 4 Siddiqui YS, Zahid M, Bin Sabir A; Julfiqar. Giant cell tumor of the first metatarsal. J Cancer Res Ther 2011;7:208-10.
  • 5 Rosenberg AE, Nielsen GP. Giant cell containing lesions of bone and their differential diagnosis. Curr Diagn Pathol 2001;7:235-46.
  • 6 Li W, Maleki Z. Giant cell tumor of bone mimicking metastatic renal cell carcinoma: A case report. Diagn Cytopathol 2012;40 Suppl 2:E169-71.
  • 7 Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G. Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol 2010;134:127-38.
  • 8 Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol 2008;66:248-61.
  • 9 Yasir S, Herrera L, Gomez-Fernandez C, Reis IM, Umar S, Leveillee R, et al. CD10+and CK7/RON immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers. Appl Immunohistochem Mol Morphol 2012;20:454-61.
  • 10 Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: A clinicopathologic study of 9 cases. Am J Surg Pathol 2008;32:752-7.
  • 11 Nunez AL, Siegal GP, Reddy VV, Wei S. CD138 (syndecan-1) expression in bone-forming tumors. Am J Clin Pathol 2012;137:423-8.
  • 12 Murata A, Fujita T, Kawahara N, Tsuchiya H, Tomita K. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005;10:581-8.
  • 13 Nishimura M, Yuasa K, Mori K, Miyamoto N, Ito M, Tsurudome M, et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res 2005;23:979-87.
  • 14 Matsubayashi S, Nakashima M, Kumagai K, Egashira M, Naruke Y, Kondo H, et al. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): A possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract 2009;205:626-33.
  • 15 Werner M. Giant cell tumour of bone: Morphological, biological and histogenetical aspects. Int Orthop 2006;30:484-9.
  • 16 Ramos RY, Haupt HM, Kanetsky PA, Donthineni-Rao R, Arenas-Elliott C, Lackman RD, et al. Giant cell tumors: Inquiry into immunohistochemical expression of CD117 (c-Kit), microphthalmia transcription factor, tartrate-resistant acid phosphatase, and HAM-56. Arch Pathol Lab Med 2005;129:360-5.
  • 17 Masui F, Ushigome S, Fujii K. Giant cell tumor of bone: An immunohistochemical comparative study. Pathol Int 1998;48:355-61.
  • 18 Ismail FW, Shamsudin AM, Wan Z, Daud SM, Samarendra MS. Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone. J Exp Clin Cancer Res 2010;29:25.